Market Research Logo

Nonalcoholic Steatohepatitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Nonalcoholic Steatohepatitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.

Market Dynamics

Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.

However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.

Key features of the study:

  • This report provides in-depth analysis of the nonalcoholic steatohepatitis treatment market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global nonalcoholic steatohepatitis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global nonalcoholic steatohepatitis treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for nonalcoholic steatohepatitis treatment market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
  • Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global Nonalcoholic Steatohepatitis Treatment Market, By Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Africa
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • By Drug:
  • Cenicriviroc
  • Elafibranor
  • Ocaliva (Obeticholic Acid)
  • Selonsertib
  • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Company Profiles
  • AstraZeneca Plc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Conatus Pharmaceuticals
  • Enzo Biochem, Inc.
  • GENFIT SA
  • Galmed Pharmaceuticals Ltd.
  • Gilead Science
  • Immuron Ltd.
  • Intercepts Pharmaceuticals
  • Novo Nordisk
  • Raptor Pharmaceutical Corporation
  • Tobira Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Research Studies
Pipeline Product Analysis
Epidemiology Study
PORTER’S Five Forces
4. Global Nonalcoholic Steatohepatitis Treatment Market, By Drug, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Cenicriviroc
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Elafibranor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Ocaliva (Obeticholic acid)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Selonsertib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
5. Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
6. Global Nonalcoholic Steatohepatitis Treatment Market, By Region, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2016 – 2026
Regional Trends
North America
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By End Use, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By End Use, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By End Use, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By End Use, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By End Use, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
Northern Africa
Central Africa
South Africa
Middle East
Market Size and Forecast, By Drug, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By End Use, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
GCC Countries
Israel
Rest of Middle East
7. Competitive Landscape
Heat Map Analysis
Company Profiles
AstraZeneca Plc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Conatus Pharmaceuticals
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Enzo Biochem, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GENFIT SA,
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Galmed Pharmaceuticals Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Gilead Science
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Immuron Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Intercepts Pharmaceuticals
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Novo Nordisk
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Raptor Pharmaceutical Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Tobira Therapeutics, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Analyst Views
8. Section
References
Research Methodology
About Us and Sales Contact
*Browse 26 market data tables and 28 figures on "Nonalcoholic Steatohepatitis Treatment Market” - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report